Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 65 (in the dose escalation phase) or aged 18 and over (in the dose expansion phase), of any gender
• People whose general health and ability to carry out daily activities meets a standard scoring level known as ECOG performance status 0 or 1 (confirm with trial site)
• In the dose escalation phase: people with a confirmed advanced or metastatic solid tumour (not liver cancer) or relapsed/returning lymphoma, whose cancer has continued to grow after standard treatments, who could not tolerate standard treatments, who have declined standard treatments, or for whom no standard treatments exist
• In the dose expansion phase: people with confirmed advanced or metastatic non-small cell lung cancer without certain gene mutations, relapsed or returning lymphoma, liver cancer (hepatocellular carcinoma) with a specific liver function score, or other solid tumours where standard treatment has failed, is not tolerated, is declined, or does not exist
• People who have at least one measurable or evaluable area of cancer that can be tracked on scans, assessed using standard measurement methods appropriate to their cancer type
• People whose organs (such as liver, kidneys, and blood system) are functioning at an adequate level

Who may not be able to join:

• In the dose escalation phase: people who have previously received certain immunotherapy drugs that target PD-1, PD-L1, or PD-L2
• In the dose expansion phase: people who have received PD-1, PD-L1, or PD-L2 immunotherapy within the 28 days before treatment starts, or people who have previously experienced a severe (Grade 3 or higher) immune-related side effect from immunotherapy
• People who have previously received certain other treatments that target specific immune cells called T cells (confirm specific agents with trial site)
• People who have been taking steroid medicines at a dose of 10 mg per day or more (or equivalent) in the two weeks before starting the trial
• People who have not waited long enough since finishing previous cancer treatments, certain other medications, or vaccines, as specified by the trial protocol (confirm timeframes with trial site)
• People who have had major surgery within the past four weeks, or who have serious unstable health conditions, active or symptomatic cancer spread to the brain, another active cancer, autoimmune disease, certain lung conditions, significant heart disease, active bleeding or clotting problems, active serious infections, difficulty swallowing or absorbing medicines, or a history of chronic diarrhoea
• People who are pregnant or breastfeeding
• People whom the trial investigators consider unsuitable to participate for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.